Fidaxomicin Metabolite OP-1118

METABOLITES

Product Details

CAT No.# CS-O-03629
Category Metabolites
CAS 1030825-28-5
Molecular Weight 987.95
Molecular Formula C48H68Cl2O17
Stock Status: In-Stock
Purity: >98%
Synonyms: Desisobutyryl Fidaxomicin;(3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-Deoxy-4-O-(3,5yl)-2-O-methyl-β-L-mannopyranosyl]oxy]methyl]-12-[(6-deoxyD-lyxo-hexopyranosyl)oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one; OP 1118; OPT 1118
Application Notes: OP-1118 is a major metabolite of Fidaxomicin .
References: Babakhani, F., et al.: Clin. Infect. Dis., 55, S162 (2012); Venugopal, A., et al.: Clin. Infect. Dis., 54, 568 (2012)
Storage: -20° C
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
O=C(C(C(O)=C(Cl)C(O)=C1Cl)=C1CC)O[C@@H]([C@@H](O[C@@H]2OC/C(C(O[C@](C/C=C3C)([H])[C@H](O)C)=O)=C\C=C\C[C@](/C(C)=C\[C@H](CC)[C@@H](O[C@@](OC(C)(C)[C@@H](O)[C@@H]4O)([H])[C@H]4O)\C(C)=C/3)([H])O)C)[C@H]([C@H]2OC)O



This page contains information about Fidaxomicin Metabolite OP-1118 Cas 1030825-28-5 and its Metabolites.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."